The9 Limited announced that its Singapore investee company, Nanyang Biologics Pte. Ltd. (NYB), entered into a business combination agreement with RF Acquisition Corp II (RFAI), a publicly traded special purpose acquisition company.
This transaction is aimed at making NYB a publicly listed company on Nasdaq under the reserved ticker symbol 'NYB.' The Proposed Transaction gives NYB approximately $1.5 billion in pre-transaction equity value.
The9, as an existing shareholder of NYB, will roll over 100% of its equity and retain a majority of the combined company's outstanding shares. The closing of the transaction is expected in the first or second quarter of 2026, subject to shareholder approvals and customary closing conditions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.